Your browser doesn't support javascript.
loading
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Brisson, Ryan J; Kochanny, Sara; Arshad, Saba; Dekker, Allison; DeSouza, Jonas A; Saloura, Vassiliki; Vokes, Everett E; Seiwert, Tanguy Y.
Affiliation
  • Brisson RJ; Oakland University William Beaumont School of Medicine, Rochester, Michigan.
  • Kochanny S; Department of Medicine, The University of Chicago Medicine, Chicago, Illinois.
  • Arshad S; Department of Medicine, Blake Medical Center, Bradenton, Florida.
  • Dekker A; Department of Medicine, The University of Chicago Medicine, Chicago, Illinois.
  • DeSouza JA; Humana, Louisville, Kentucky.
  • Saloura V; National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Vokes EE; Department of Medicine, The University of Chicago Medicine, Chicago, Illinois.
  • Seiwert TY; The University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
Head Neck ; 41(11): 3842-3849, 2019 11.
Article in En | MEDLINE | ID: mdl-31486207
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Morpholines / Cetuximab / Antineoplastic Agents, Immunological / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms / Aminopyridines / Neoplasm Recurrence, Local Type of study: Guideline Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Morpholines / Cetuximab / Antineoplastic Agents, Immunological / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms / Aminopyridines / Neoplasm Recurrence, Local Type of study: Guideline Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article